Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China · Delayed Price · Currency is CNY 18.44
+0.28 (1.54%)
Feb 3, 2026, 2:55 PM CST
Hybio Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 855.1 | 547.2 | 383.13 | 692.29 | 730.93 | 714.01 |
Other Revenue | 43 | 43 | 48.25 | 12.03 | 5.04 | 7.71 |
| 898.1 | 590.2 | 431.38 | 704.32 | 735.97 | 721.72 | |
Revenue Growth (YoY) | 121.72% | 36.81% | -38.75% | -4.30% | 1.97% | 17.51% |
Cost of Revenue | 404.07 | 281.47 | 260.42 | 194.83 | 271.88 | 153.54 |
Gross Profit | 494.03 | 308.73 | 170.97 | 509.49 | 464.1 | 568.18 |
Selling, General & Admin | 251.81 | 240.13 | 367.6 | 484.36 | 545.43 | 536.99 |
Research & Development | 102.12 | 87.33 | 159.6 | 154.79 | 101.94 | 140.21 |
Other Operating Expenses | 27.8 | 8.13 | 12.22 | 16.52 | 16.78 | 11.72 |
Operating Expenses | 382.03 | 341.14 | 542.38 | 691.62 | 734.37 | 1,113 |
Operating Income | 112 | -32.41 | -371.41 | -182.13 | -270.27 | -545.25 |
Interest Expense | -100.15 | -106.5 | -120.46 | -103.25 | -87.92 | -59.24 |
Interest & Investment Income | 4.84 | 1.9 | 0.22 | 0.57 | 391.46 | 18.86 |
Currency Exchange Gain (Loss) | 3.64 | 3.64 | 0.29 | 1.64 | -1.55 | -4.37 |
Other Non Operating Income (Expenses) | -13.16 | -10.45 | -11.2 | -10.01 | -16.22 | -9.41 |
EBT Excluding Unusual Items | 7.16 | -143.82 | -502.57 | -293.18 | 15.48 | -599.41 |
Gain (Loss) on Sale of Investments | 0.68 | - | 34.71 | -89.77 | -16.47 | - |
Gain (Loss) on Sale of Assets | 0.68 | 42.78 | -0.51 | 3.41 | 35.2 | -0.95 |
Asset Writedown | -94.94 | -82.43 | -90.81 | -17.51 | -41.99 | -10.86 |
Legal Settlements | - | - | - | - | -1.24 | - |
Other Unusual Items | 39.21 | 21.06 | 48.08 | 24.24 | 42.71 | 22.99 |
Pretax Income | -47.2 | -162.41 | -511.1 | -372.81 | 33.68 | -588.24 |
Income Tax Expense | 27.3 | 17.68 | 4.34 | -0.27 | 5.24 | 21.06 |
Earnings From Continuing Operations | -74.51 | -180.09 | -515.44 | -372.55 | 28.44 | -609.3 |
Minority Interest in Earnings | 7.01 | 6.44 | 1.57 | 2 | 2.37 | -0.13 |
Net Income | -67.5 | -173.65 | -513.88 | -370.55 | 30.81 | -609.43 |
Net Income to Common | -67.5 | -173.65 | -513.88 | -370.55 | 30.81 | -609.43 |
Shares Outstanding (Basic) | 885 | 868 | 886 | 882 | 1,027 | 923 |
Shares Outstanding (Diluted) | 885 | 868 | 886 | 882 | 1,027 | 923 |
Shares Change (YoY) | 2.67% | -2.00% | 0.42% | -14.09% | 11.21% | 0.19% |
EPS (Basic) | -0.08 | -0.20 | -0.58 | -0.42 | 0.03 | -0.66 |
EPS (Diluted) | -0.08 | -0.20 | -0.58 | -0.42 | 0.03 | -0.66 |
Free Cash Flow | 128.89 | 48.87 | -85.3 | -174.04 | -42.17 | -195.67 |
Free Cash Flow Per Share | 0.15 | 0.06 | -0.10 | -0.20 | -0.04 | -0.21 |
Gross Margin | 55.01% | 52.31% | 39.63% | 72.34% | 63.06% | 78.72% |
Operating Margin | 12.47% | -5.49% | -86.10% | -25.86% | -36.72% | -75.55% |
Profit Margin | -7.52% | -29.42% | -119.12% | -52.61% | 4.19% | -84.44% |
Free Cash Flow Margin | 14.35% | 8.28% | -19.77% | -24.71% | -5.73% | -27.11% |
EBITDA | 255.8 | 113.52 | -222.64 | -52.6 | -144.93 | -440.71 |
EBITDA Margin | 28.48% | 19.23% | -51.61% | -7.47% | -19.69% | -61.06% |
D&A For EBITDA | 143.8 | 145.93 | 148.77 | 129.53 | 125.35 | 104.54 |
EBIT | 112 | -32.41 | -371.41 | -182.13 | -270.27 | -545.25 |
EBIT Margin | 12.47% | -5.49% | -86.10% | -25.86% | -36.72% | -75.55% |
Effective Tax Rate | - | - | - | - | 15.57% | - |
Revenue as Reported | 898.1 | 590.2 | 431.38 | 704.32 | 735.97 | 721.72 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.